X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (70) 70
Publication (8) 8
Book / eBook (4) 4
Newspaper Article (3) 3
Book Review (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
index medicus (37) 37
female (18) 18
male (18) 18
hematology (17) 17
abridged index medicus (12) 12
aged (12) 12
anticoagulants (12) 12
middle aged (12) 12
peripheral vascular disease (12) 12
administration, oral (10) 10
hemorrhage - chemically induced (10) 10
hemorrhage - drug therapy (10) 10
rivaroxaban (10) 10
adult (9) 9
dabigatran (9) 9
management (9) 9
prothrombin complex concentrate (9) 9
analysis (8) 8
anticoagulants - adverse effects (8) 8
apixaban (8) 8
atrial-fibrillation (8) 8
bleeding (8) 8
mortality (8) 8
reversal (8) 8
risk factors (8) 8
anticoagulants - therapeutic use (7) 7
factor-xa inhibitor (7) 7
medicine, general & internal (7) 7
dabigatran etexilate (6) 6
direct thrombin inhibitor (6) 6
dosage and administration (6) 6
international normalized ratio (6) 6
plasma (6) 6
risk (6) 6
warfarin (6) 6
activated factor-vii (5) 5
antithrombotic therapy (5) 5
cardiac & cardiovascular systems (5) 5
health aspects (5) 5
hemorrhage (5) 5
in-vitro (5) 5
medical research (5) 5
united states (5) 5
venous thromboembolism (5) 5
acute disease (4) 4
adolescent (4) 4
anticoagulants - pharmacology (4) 4
antithrombins - pharmacology (4) 4
article (4) 4
care and treatment (4) 4
drug therapy (4) 4
factor xa - therapeutic use (4) 4
factor xa inhibitors - adverse effects (4) 4
hemostasis (4) 4
laboratory (4) 4
medicine, experimental (4) 4
oral anticoagulants (4) 4
patients (4) 4
prevention (4) 4
pyrazoles - adverse effects (4) 4
pyridones - adverse effects (4) 4
recombinant proteins - therapeutic use (4) 4
research (4) 4
surveys and questionnaires (4) 4
thrombosis (4) 4
women (4) 4
aged, 80 and over (3) 3
animals (3) 3
anticoagulants - administration & dosage (3) 3
antithrombins - adverse effects (3) 3
atrial fibrillation - drug therapy (3) 3
attitude to health (3) 3
beta-alanine - analogs & derivatives (3) 3
blood coagulation - drug effects (3) 3
cardiology (3) 3
child (3) 3
child, preschool (3) 3
coagulation (3) 3
diagnosis (3) 3
double-blind (3) 3
double-blind method (3) 3
factor xa inhibitors - therapeutic use (3) 3
further section (3) 3
health (3) 3
immunology (3) 3
intracerebral hemorrhage (3) 3
intracranial hemorrhage (3) 3
morpholines - pharmacology (3) 3
oncology (3) 3
partial thromboplastin time (3) 3
prevalence (3) 3
prothrombin time (3) 3
public, environmental & occupational health (3) 3
pulmonary embolism (3) 3
randomized controlled trials as topic (3) 3
risk assessment (3) 3
surgery (3) 3
thiophenes - pharmacology (3) 3
thrombin (3) 3
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
OISE - Stacks (3) 3
Robarts - Stacks (3) 3
New College (Ivey) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Media Commons - Microtexts (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis Research, ISSN 0049-3848, 08/2019, Volume 180, pp. 86 - 86
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2013, Volume 34, Issue 7, pp. 489 - 500
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous... 
Novel oral anticoagulants | Bleeding | Management | RECOMBINANT FACTOR-VIIA | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | RANDOMIZED EVALUATION | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | FACTOR-XA INHIBITOR | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | NONVALVULAR ATRIAL-FIBRILLATION | Plasma | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | beta-Alanine - pharmacology | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Acute Disease | beta-Alanine - adverse effects | Administration, Oral | Morpholines - administration & dosage | Risk Factors | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Anticoagulants - pharmacology | Antithrombins - adverse effects | Blood Coagulation Tests | Benzimidazoles - pharmacology | Aged | Hemostatics - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Renal Dialysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
BMJ Case Reports, ISSN 1757-790X, 04/2019, Volume 12, Issue 4, p. e228546
A 52-year-old man presented with chronic urticaria that was refractory to standard chronic spontaneous urticaria (CSU) treatment. Over time, he developed... 
Hematology | Laboratories | Anemia | Neutrophils | Systematic review | Family medical history | Medical diagnosis | Patients | Allergies | Asthma | Proteins | Immunology | Hemoglobin
Journal Article
Hematology, ISSN 1520-4391, 12/2014, Volume 2014, Issue 1, pp. 334 - 336
Journal Article